WO2018155865A1 - Bandelette d'analyse de sang - Google Patents

Bandelette d'analyse de sang Download PDF

Info

Publication number
WO2018155865A1
WO2018155865A1 PCT/KR2018/001995 KR2018001995W WO2018155865A1 WO 2018155865 A1 WO2018155865 A1 WO 2018155865A1 KR 2018001995 W KR2018001995 W KR 2018001995W WO 2018155865 A1 WO2018155865 A1 WO 2018155865A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood
channel
chamber
state
collected
Prior art date
Application number
PCT/KR2018/001995
Other languages
English (en)
Korean (ko)
Inventor
김원동
김근영
Original Assignee
(주)오상헬스케어
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)오상헬스케어 filed Critical (주)오상헬스케어
Publication of WO2018155865A1 publication Critical patent/WO2018155865A1/fr

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/491—Blood by separating the blood components
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502761—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads, for physically stretching molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06—Fluid handling related problems
    • B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
    • B01L2200/0652—Sorting or classification of particles or molecules
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/10—Integrating sample preparation and analysis in single entity, e.g. lab-on-a-chip concept
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0681—Filter

Definitions

  • the present invention relates to a strip for blood analysis, and more specifically, glucose, ketone, albumin, glycated hemoglobin (HbA1c) in blood by optical methods and / or electromagnetic methods, etc.
  • the present invention relates to a strip for blood analysis that can be used for analysis of hormones, minerals, lipids, proteins, vitamins, hemoglobin, and the like.
  • Blood circulating in the blood vessels of a human or animal body carries oxygen from the lungs to tissue cells, carries carbon dioxide from the tissues to the lungs, releases it out, transports nutrients absorbed from the digestive tract to organs or tissue cells, As a decomposition product of, it transports substances that are unnecessary to the living body to the kidneys and discharges them out of the body, carries hormones secreted from the endocrine glands to the working organs and tissues, distributes body heat evenly, maintains constant body temperature, and invades the living body It performs various functions such as destroying and detoxifying bacteria and foreign substances.
  • Such blood may be a sample to be analyzed for a variety of purposes, including glucose, ketones, albumin, glycated hemoglobin (HbA1c), hormones, minerals, lipids in the blood. ), Protein (vitamin), hemoglobin (hemoglobin), etc. can be analyzed to predict the abnormal signs of the body or determine the current state.
  • the amount of glucose is a factor that can induce diabetes. If the amount of glucose is high, it causes diabetes. On the contrary, a small amount of glucose causes serious problems such as abnormal symptoms in the central nervous system.
  • the method using the light of measuring the amount of glucose is to measure the amount of glucose by irradiating light to the blood to analyze the received light.
  • the obstacle is the reality.
  • hemoglobin hemoglobin
  • An object of the present invention is to provide glucose, ketone, albumin, glycated hemoglobin (HbA1c), hormone (hormone), mineral (mineral), in the blood by optical methods and / or electromagnetic methods. It provides a strip inserted into a sample measuring device that can analyze lipids, proteins, vitamins, hemoglobin, and the like. By providing a separate strip for blood analysis to maximize the accuracy of the analysis.
  • HbA1c glycated hemoglobin
  • hormone hormone
  • mineral mineral
  • the blood analysis strip is inserted into a sample measuring device, wherein the sample measuring device is configured to analyze a specific component contained in blood by an optical method and / or an electromagnetic method.
  • the blood cells are formed into a capillary tube so that the blood of the second state is filtered in the process of flowing into the second channel, and the second channel is formed by the blood cells in the process of introducing the blood collected in the first chamber into the second channel. It may be characterized in that it is formed into a capillary tube, so that the filtered blood of the third state.
  • the blood of the second 'state in which the blood cells are reduced from the blood of the second state is reduced. It may be characterized in that it is formed to reduce the cross-sectional area along the inflow direction of the blood to be introduced into one chamber.
  • the blood of the third 'state in which blood cells are reduced from the blood of the third state is reduced. It may be characterized in that the cross-sectional area along the inflow direction of the blood is reduced to be introduced into the two chambers.
  • the first chamber of the blood analysis strip is such that the blood of the third state is collected in the second chamber after flowing into the second channel by capillary action, the first chamber It may have a channel and a space larger than the second channel.
  • the second chamber of the blood analysis strip may have a larger space than the second channel to secure an analysis area of a specific component included in the blood.
  • the first blood processing unit is provided in the first chamber so that the processed blood flows into the second channel by processing the blood collected in the first chamber; It may be characterized in that it further comprises.
  • the first blood processing unit of the blood analysis strip according to an embodiment of the present invention, the filter to pass the blood plasma in the blood collected in the first chamber, filtering the blood cells, blood cells in the blood collected in the first chamber It may be characterized in that it comprises at least one of a coagulant for coagulation and a hemolytic agent for hemolysis of red blood cells in the blood collected in the first chamber.
  • the blood cells are collected in the blood collected in the second chamber to collect the specific component based on the plasma contained in the blood collected in the second chamber by the controller And a second blood processing unit provided in the second chamber to be analyzed.
  • the first blood processing unit may be at least one of salt, beads, and fragments for dNTP buffer or lysis for genetic analysis.
  • the second chamber of the blood analysis strip according to an embodiment of the present invention may be exposed to the outside.
  • blood cells and plasma in the blood are separated from each other by an effective and simple method, such as glucose, ketone, and blood in the blood by an optical method and an electromagnetic method. It is possible to maximize the accuracy of the analysis of albumin, glycated hemoglobin (HbA1c), hormones, minerals, lipids, proteins, vitamins, hemoglobin, etc. .
  • HbA1c glycated hemoglobin
  • FIGS. 2 and 3 are schematic perspective and exploded perspective views showing a strip for blood analysis according to a first embodiment of the present invention.
  • Figure 4 is a schematic exploded perspective view showing a strip for blood analysis according to a second embodiment of the present invention.
  • FIG. 5 is a schematic exploded perspective view showing a strip for blood analysis according to a third embodiment of the present invention.
  • Figure 6 is a schematic exploded perspective view showing a strip for blood analysis according to a fourth embodiment of the present invention.
  • FIG. 7 is a schematic exploded perspective view showing a strip for blood analysis according to a fifth embodiment of the present invention.
  • FIG. 1 is a view for explaining the principle that a specific component of blood is analyzed by a sample measuring device.
  • the blood analysis strip (100, hereinafter referred to as 'strip') such as glucose (keco), ketone (keton), in the blood by a spectroscopic method and / or an electromagnetic method, etc.
  • a sample measuring device that can analyze albumin (albumin), glycated hemoglobin (HbA1c), hormone (hormone), mineral (mineral), lipid (lipid), protein (protein), vitamin (vitamin), hemoglobin It may be a strip to be inserted.
  • the strip 100 may be a strip used for gene amplification for gene analysis, nucleic acid extraction for nucleic acid analysis, and various other purposes.
  • the blood analysis strip 100 may be capable of stimulating thermal, physical, optical, and electrical (electrophoresis, electrophoresis, etc.) in the sample measuring device, and the sample measuring device may include the blood analysis strip 100.
  • a correction algorithm may be applied to correct blood phase or characteristics of processes, for example, external environmental factors such as temperature or humidity.
  • the sample measuring device may be a device capable of analyzing a specific component in blood by an optical method and / or an electromagnetic method, but is not limited thereto, and may be specified by an electrochemical method or a physical invasion method. It may be a device capable of analyzing the components.
  • the optical method may mean a method capable of analyzing the concentration of the specific component or the like based on the property of the light irradiated to the blood by the specific component included in the blood.
  • the strip 100 according to the present invention is glucose (kecose), ketone (keton), albumin (albumin), glycated hemoglobin (HbA1c), hormone (hormone), mineral ( It may be a strip that separates blood cells and plasma so that specific components such as minerals, lipids, proteins, vitamins, hemoglobin, etc. can be analyzed, but below the concentration of glucose
  • the purpose of the strip 100 according to the present invention is not limited to the purpose for measuring the concentration of glucose.
  • light may be irradiated to the plasma, and the light irradiated to the plasma containing glucose used in the optical method may be infrared light, that is, a wavelength range of 800-2,500 nm. It may be near infrared (NIR) or mid infrared (MIR) in the wavelength range of 2,500-10,000 nm.
  • NIR near infrared
  • MIR mid infrared
  • the light may be reflected or transmitted with scattering by the glucose contained in the plasma.
  • the concentration of glucose may be measured based on light reflected with scattering, and scattering may be performed. It is also possible to measure the concentration of glucose based on the light transmitted while accompanying.
  • the optical method can analyze a specific component in the blood in either a reflection type or a transmission type.
  • concentration of glucose When measuring the concentration of glucose based on the reflected light with the scattering, spectroscopy the received light to obtain a spectrum, and based on the acquired spectrum, a dynamic spectrum representing a change in the spectrum over time is obtained.
  • the concentration of glucose may be measured by comparing the generated dynamic spectrum with previously stored concentration-specific dynamic spectrum.
  • the concentration of glucose when measuring the concentration of glucose based on the light transmitted with the scattering, the concentration of glucose can be measured based on the amount of change in the intensity of light received based on the intensity of light irradiated to the plasma.
  • the degree of scattering of light is determined based on the number of particles of glucose in the plasma. That is, the more particles, the less scattering of light. When the scattering of light is reduced, the distance that light passes through the plasma becomes shorter. Decreases the rate of decrease.
  • the specimen measuring device includes a light emitting part (X) for irradiating the plasma containing glucose and a light receiving part for receiving the light irradiated from the light emitting part (X). (Y1, Y2), a control unit (not shown) for calculating the concentration of glucose based on the light received by the light receiving unit (Y1, Y2).
  • the light receiving units Y1 and Y2 measure the concentration of glucose based on the light receiving unit Y1 for measuring glucose concentration and / or the light transmitted while scattering, based on the light reflected with scattering.
  • the light receiving unit Y2 may be included.
  • light and analysis data that can be used in analyzing a specific component contained in the blood in the optical method is not limited to the above-mentioned, it may use a monochromatic light or multiple wavelengths of various spectra, absorbance, luminance, Analysis may also be made through reflectance, spectrum, colorimetry, and / or color pattern.
  • FIGS. 2 and 3 are a schematic perspective view and a schematic exploded perspective view showing a strip for blood analysis according to a first embodiment of the present invention.
  • the strip 100 according to the first embodiment of the present invention is a strip inserted into a sample measuring apparatus for measuring the concentration of glucose described with reference to FIG. 1. It may be a strip that allows plasma to be separated from each other by an effective and simple method to maximize the accuracy of the measurement of glucose concentration.
  • blood contains blood cells, such as red blood cells, and the like, because blood cells, etc., are relatively large in size compared to the plasma containing glucose, thereby impeding the measurement of blood glucose by spectroscopic method, thereby increasing the concentration of glucose. Accurate measurement requires the separation of blood cells and plasma.
  • the strip 100 is the blood inlet 121, the first channel 122, the first chamber 123, the second channel 124, the second chamber 125 and Third channel 126 and the like.
  • the blood inlet 121 may be a component provided to receive the blood B1 in a first state including plasma and blood cells, and is formed such that the cross-sectional area along the moving direction of the blood is reduced linearly or nonlinearly. Can be.
  • the first channel 122 may be a channel for introducing the blood B1 of the first state received in the blood inlet 121 into the second state by a capillary phenomenon.
  • the first chamber 123 may be a chamber in which the blood B2 of the second state introduced into the first channel 122 passes through the first channel 122 and is collected.
  • the channel 124 may be a channel for introducing blood collected in the first chamber 123 into a third state by capillary action.
  • the second chamber 125 may be a chamber in which the blood B3 of the third state introduced into the second channel 124 passes after passing through the second channel 124.
  • Channel 126 is an optional component and may be a channel communicating with the outside to improve capillary phenomenon.
  • the blood B1 of the first state, the blood B2 of the second state, and the blood B3 of the third state are terms defined to distinguish blood according to the amount of blood cells contained in the blood. .
  • the blood inlet 121, the first channel 122, the first chamber 123, the second channel 124, the second chamber 125 and the third channel 126 are predetermined spaces.
  • the intermediate layer 120 having a predetermined size, the upper layer 110 and the lower layer 130 of a predetermined size bonded to the upper and lower sides of the intermediate layer 120, respectively.
  • the intermediate layer 120, the upper layer 110 and the lower layer 130 may be formed of a material that does not absorb blood, the upper layer 110 and the lower layer 130 is a material that can transmit light, For example, it may be formed of a transparent material.
  • the blood inlet 121, the first channel 122, the first chamber 123, the second channel 124, the second chamber 125 and the third channel 126 may be formed in the intermediate layer ( The size may be determined by a predetermined space of 120, but is not necessarily limited thereto.
  • a space is formed in at least one of the upper layer 110 and the lower layer 130, and the components may be implemented by the sum of the spaces.
  • the third channel 126 may be implemented by a space formed in at least one of the upper layer 110 and the lower layer 130 to prevent separation of the intermediate layer.
  • the blood inlet 121, the first channel 122, the first chamber 123, the second channel 124, the second chamber 125 and the third channel 126 are The case where the size is determined by a predetermined space of the intermediate layer 120 will be described as an example.
  • the predetermined space formed in the intermediate layer 120 may be covered by an upper side and a lower side by the upper layer 110 and the lower layer 130.
  • the first channel 122 may be formed as a capillary tube so that the blood B2 of the second state, from which blood cells are filtered, is introduced while the blood B1 of the first state flows into the first channel 122.
  • the blood B3 of the third state in which the blood cells are filtered is introduced while the blood collected in the first chamber 123 flows into the second channel 124. It may be formed as a capillary tube.
  • the first channel 122 is formed as a capillary, relatively large blood cells are primarily filtered in the blood B1 in the first state accommodated in the blood inlet 121 to reduce the amount of blood cells. Blood B2 in two states is introduced into the first channel 122.
  • the second channel 124 is formed as a capillary tube, blood cells having a relatively large size in the blood collected in the first chamber 123 are secondarily filtered to reduce the amount of blood cells. (B3) is introduced into the second channel 124, and finally the blood is minimized the amount of blood cells are collected in the second chamber (125).
  • the light emitting unit X of the sample measuring device irradiates light to the blood in the second chamber 125, and the light receiving unit Y1, After Y2) receives the light, a specific component contained in blood in the second chamber 125 is analyzed by the controller.
  • the specimen measuring device may irradiate light to blood in the first chamber 123 to analyze specific components (eg, hemoglobin concentration, etc.) of blood in the first chamber 123 based on the light. .
  • the blood in the blood of the first chamber 123 and the blood of the second chamber 125 may be irradiated simultaneously or sequentially so that different specific components of blood may be analyzed based on the light.
  • the first chamber 123 is the blood (B3) of the third state is introduced into the second channel 124 by the capillary phenomenon, and then collected in the second chamber 125, the first A space larger than the channel 122 and / or the second channel 124 may be provided.
  • first channel 122 and the middle in order to maximize the movement force of the blood by the capillary phenomenon that is the source of the force that can move the blood from the first channel 122 to the second channel 124 A larger space than the second channel 124 is required, and the first chamber 123 is required for this purpose.
  • the sample measuring device when the specific component (eg, hemoglobin concentration, etc.) of the blood in the first chamber 123 is analyzed by the sample measuring device due to the spatial characteristics as described above of the first chamber 123, the sample measuring device The irradiation area of the light emitted from the light emitting portion X can be increased.
  • specific component eg, hemoglobin concentration, etc.
  • the first chamber 123 may have a shape that becomes wider and narrower along a moving direction of blood, and may be, for example, an ellipse, but is not limited thereto.
  • the second chamber 125 may have a larger space than the second channel 124 in order to increase the irradiation area of the light emitted by the light emitting unit X of the specimen measuring device.
  • glucose concentration measurement by spectroscopic method targeting blood including plasma collected in the second chamber 125 may be more accurate.
  • the second chamber 125 may have a shape that is widened and narrowed along a moving direction of blood, and may be, for example, an ellipse, but is not limited thereto.
  • the first channel 122 and the second channel 124 may have a constant cross-sectional area in a blood moving direction, but may be different in cross-sectional area according to a moving direction of blood as described below.
  • the third channel 126 may be a channel communicating with the outside to improve the capillary phenomenon, the blood from the blood inlet 121 by the capillary phenomenon without the third channel 126 from the second chamber If so, the third channel 126 can be omitted.
  • capillary phenomena are caused by intermolecular adhesion, ie, intermolecular adhesion of blood, they can also occur in closed channels without the third channel 126.
  • the blood analysis strip according to the present invention includes two chambers, two or three channels, but is not necessarily limited thereto, and the number of chambers or the number of channels is changed as necessary. It can be revealed.
  • FIG. 4 is a schematic exploded perspective view showing a strip for blood analysis according to a second embodiment of the present invention.
  • the strip 200 may include a first channel 222 and the second channel 224, and the first channel 222 and the first channel 222. At least one of the two channels 224 may be formed such that the cross-sectional area along the direction of blood movement is reduced (in FIG. 4, both the first channel 222 and the second channel 224 are along the direction of blood movement). Is shown to be reduced).
  • the blood in the second 'state in which the blood cells are reduced from the blood B2 in the second state is reduced in the first chamber 223.
  • the cross-sectional area along the inflow direction of blood may be reduced.
  • the blood of the third 'state in which blood cells are reduced from the blood B3 of the third state is reduced in the second chamber 225.
  • the cross-sectional area along the inflow direction of blood may be reduced.
  • the amount of blood cells contained in the blood can be naturally filtered while passing through the first channel 222 and the second channel 224, so that the effect of blood cell removal becomes more remarkable.
  • FIG. 5 is a schematic exploded perspective view showing a strip for blood analysis according to a third embodiment of the present invention
  • FIG. 6 is a schematic exploded perspective view showing a strip for blood analysis according to a fourth embodiment of the present invention.
  • the upper layer 310 may include an upper exposure part 315 formed through the second chamber 325 to be exposed to the outside.
  • Plasma collected in the second chamber 325 due to the upper exposure portion 315 may be exposed to the outside.
  • each of the upper layer 410 and the lower layer 430 may include an upper exposed portion 415 and a lower exposed portion 435 formed through the second chamber 425 so as to be exposed to the outside. .
  • FIG. 7 is a schematic exploded perspective view showing a strip for blood analysis according to a fifth embodiment of the present invention.
  • the strip 500 allows a specific process to be performed based on the blood collected in the first chamber 523 so that the blood after the specific process is performed is It may include a first blood processing unit 550 to be introduced into the second channel 524.
  • the first blood processing unit 550 is connected to the first chamber 523. It may be a component provided in the first chamber 523 to reduce the blood cell amount of the blood (B3) of the third state flowing into the second channel 524 by collecting blood cells in the collected blood. .
  • the first blood processing unit 550 may be a kind of filter that allows blood to pass through the plasma, but filters the blood cells of a relatively large size, and the second channel 524 in the first chamber 523. Any position may be provided as long as it does not block the entrance.
  • the first blood processing part 550 may be a filter formed of paper, glass fiber, nanofiber, porous layer medium, polymer separation membrane, or the like. It may be formed of one or several layers of multilayers, but is not necessarily limited thereto, and any one having a characteristic of filtering blood cells and passing only plasma may be applicable.
  • the first blood processing unit 550 when the first blood processing unit 550 is implemented with the above-described filter, it may be possible to control whether or not filtering or the degree of filtering, internally or externally.
  • the first blood processing unit 550 is not limited to a filter, but a coagulant that coagulates blood cells in the blood collected in the first chamber 523 and / or hemolyzes the red blood cells in the blood.
  • a coagulant that coagulates blood cells in the blood collected in the first chamber 523 and / or hemolyzes the red blood cells in the blood.
  • Eg hemoglobin, lymphocytes, etc. may be a hemolytic agent to be analyzed.
  • the coagulant may be silica particles, citric acid, or the like, but is not necessarily limited thereto, and any coagulant may be used as long as it can coagulate blood cells.
  • the hemolytic agent may be Lysercell or the like.
  • the sample measuring device may be applied to the blood hemolyzed by the hemolytic agent in the first chamber 123.
  • the light may be irradiated with respect to a specific component (eg, hemoglobin concentration, etc.) of blood in the first chamber 123 based on the light.
  • the first blood processing unit 550 may be various reagents or enzymes in addition to the coagulant and / or hemolytic agent.
  • the coagulant, hemolytic agent, various reagents and / or enzymes may be provided in at least one of the first channel and the second channel.
  • the first blood processing unit 550 does not necessarily have to be provided with the above-described filter, a coagulant and / or a hemolytic agent independently, and the filter and a coagulant and / or a hemolytic agent are simultaneously provided in the first chamber 523.
  • the second chamber 525 collects blood cells in the blood collected in the second chamber 525 so that the second chamber 525 is controlled by the control unit of the sample measuring device.
  • a second blood processing unit may be provided to allow a specific component to be analyzed based on the plasma contained in the blood collected in the).
  • the second blood processing unit may have the same configuration as the first blood processing unit 550, but preferably implemented as a filter.
  • the second blood processing unit when the second blood processing unit is implemented as a filter, it may be possible to control whether the filtering or the degree of filtering, internally or externally.
  • the first blood processing unit 550 may be a dNTPs buffer and may further include a porous membrane for physical filtering. .
  • the strip 500 may include a third chamber in addition to the first chamber 523 and the second chamber 525, and the third channel 126 may include the second chamber 525 and the third chamber. It can function as a connection channel for connecting.
  • the strip 500 may include a fourth channel, which is a channel communicating with the outside of the third chamber to improve a capillary phenomenon.
  • the second blood processing part which may be provided in the second chamber 525 may be a polymerize which is a kind of enzyme, and thus, the blood flowing into the second chamber 525 may be the second blood processing part. After mixing with the polymerize, it is introduced into the third chamber through the third channel 126 and combined with the primer provided in the third chamber.
  • the first blood processing unit 550 may be a salt, a bead, a treatment, or the like.
  • the second blood processing unit may be a washing solution for cleaning.
  • the column to which the hydroxyl group is attached may be chemically filtered so that only the nucleic acid that needs to be analyzed may remain, and the remaining proteins or lipids may be separated and then the beads may be illuminated.
  • a known material for chemical filtering may be present as the second blood processing part in the third chamber, and the third chamber may be implemented in plural.
  • the first blood processing unit 550 may be formed of a lysercell or surfactant, and nanofibers to separate blood cells, and the second blood processing unit may be implemented with various reactive enzymes to form specific substances in the blood. Can be analyzed.
  • the measurement of a specific substance may proceed through an external response stimulus.
  • the size, number, direction of travel of the first channel, the second channel, and the third channel may be variously changed within the spirit and scope of the present invention.
  • the size, number, shape, etc. of the first chamber and the second chamber may also be variously changed within the spirit and scope of the present invention.
  • the present invention may be arranged in a plane or at least one of at least one of the first channel, the second channel, the third channel, the first chamber, and the second chamber.
  • the present invention may form another channel and another chamber in addition to the first channel, the second channel, the third channel, the first chamber and the second chamber according to the type of the specific component. have.

Abstract

Selon un mode de réalisation, la présente invention concerne une bandelette d'analyse de sang sous la forme d'une bandelette qui s'insère dans un dispositif de mesure d'échantillon de façon qu'une substance spécifique contenue dans le sang soit analysée, ladite bandelette comprenant : un orifice d'admission pour le sang destiné à introduire le sang à un premier état ; un premier canal pour permettre au sang au premier état, qui a été introduit dans l'orifice d'admission pour le sang, de s'écouler dans celui-ci à un deuxième état par un phénomène capillaire ; une première chambre pour collecter le sang au deuxième état, qui s'est écoulé dans le premier canal, après avoir traversé le premier canal ; un second canal pour permettre au sang, qui a été collecté dans la première chambre, de s'écouler dans celui-ci à un troisième état par un phénomène capillaire ; et une seconde chambre pour collecter le sang au troisième état, qui s'est écoulé dans le second canal, après avoir traversé le second canal.
PCT/KR2018/001995 2017-02-27 2018-02-19 Bandelette d'analyse de sang WO2018155865A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0025383 2017-02-27
KR1020170025383A KR20180099964A (ko) 2017-02-27 2017-02-27 혈액 분석용 스트립

Publications (1)

Publication Number Publication Date
WO2018155865A1 true WO2018155865A1 (fr) 2018-08-30

Family

ID=63252802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/001995 WO2018155865A1 (fr) 2017-02-27 2018-02-19 Bandelette d'analyse de sang

Country Status (2)

Country Link
KR (1) KR20180099964A (fr)
WO (1) WO2018155865A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110736830A (zh) * 2019-11-18 2020-01-31 威尚生物技术（合肥）有限公司 一种用于自身免疫胶体金的检测卡

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020110486A1 (en) * 1998-07-20 2002-08-15 Shartle Robert Justice Analyte test strip with two controls
US20050069459A1 (en) * 2003-09-26 2005-03-31 The University Of Cincinnati On-chip sample preparation for whole blood analysis
JP2007509633A (ja) * 2003-10-30 2007-04-19 日立化成工業株式会社 全血からのｍＲＮＡを高効率に定量するための装置及び方法
KR100735898B1 (ko) * 2006-08-25 2007-07-04 한국기계연구원 휴대용 미세 혈액 분리기
KR20080052036A (ko) * 2006-12-07 2008-06-11 한국전자통신연구원 혈액 중의 혈장 분리를 위하여 마이크로채널을 이용한혈장분리기 및 이에 의한 혈장분리방법
KR20150009745A (ko) * 2013-07-17 2015-01-27 주식회사 미코 바이오 센서 칩

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020110486A1 (en) * 1998-07-20 2002-08-15 Shartle Robert Justice Analyte test strip with two controls
US20050069459A1 (en) * 2003-09-26 2005-03-31 The University Of Cincinnati On-chip sample preparation for whole blood analysis
JP2007509633A (ja) * 2003-10-30 2007-04-19 日立化成工業株式会社 全血からのｍＲＮＡを高効率に定量するための装置及び方法
KR100735898B1 (ko) * 2006-08-25 2007-07-04 한국기계연구원 휴대용 미세 혈액 분리기
KR20080052036A (ko) * 2006-12-07 2008-06-11 한국전자통신연구원 혈액 중의 혈장 분리를 위하여 마이크로채널을 이용한혈장분리기 및 이에 의한 혈장분리방법
KR20150009745A (ko) * 2013-07-17 2015-01-27 주식회사 미코 바이오 센서 칩

Also Published As

Publication number Publication date
KR20180099964A (ko) 2018-09-06

Similar Documents

Publication Publication Date Title
Olive et al. Detection of etoposide resistance by measuring DNA damage in individual Chinese hamster cells
Azen et al. Genetic polymorphism of human salivary proline-rich proteins: further genetic analysis
JP5320510B2 (ja) 細胞分析装置
EP0967954B1 (fr) DISPOSITIF POUR la détermination de la concentration des matériaux génants dans un PLASMA
WO2020067742A1 (fr) Dispositif de détection de fluorescence d'amplification en chaîne par polymérase, en temps réel
US20060051265A1 (en) Apparatus and method for sorting microstructures in a fluid medium
ATE461444T1 (de) Vorrichtung und verfahren zur untersuchung von analyten in flüssigsuspension oder lösung
US20030114785A1 (en) Blood analyzing method and apparatus
EP0294524B1 (fr) Appareil d'électrophorèse avec balayage en temps réel pour l'analyse de séquence d'ADN
WO2016013770A1 (fr) Puce à pcr multiplexe et dispositif de pcr multiplexe la comprenant
WO2018155865A1 (fr) Bandelette d'analyse de sang
JP5580117B2 (ja) 細胞分析装置
WO2019035565A2 (fr) Procédé de dépistage d'un patient atteint d'un cancer de la prostate basé sur un variant de récepteur d'androgènes
US9983197B2 (en) Low-cost portable microfluidic system for cell migration
CN108319815A (zh) 一种用于细胞虚拟染色的方法及其系统
Shakeel et al. Surface-enhanced Raman spectroscopic analysis of centrifugally filtered blood serum samples of hepatitis C patients
EP3801903A1 (fr) Dispositif microfluidique pour la concentration de particules
WO2019203486A1 (fr) Procédé de mesure de concentration en fibrinogène dans un échantillon de sang, et nanoparticules associées
WO2023249252A1 (fr) Biomarqueurs pour le diagnostic du cancer du poumon et procédé permettant de fournir des informations basées sur l'intelligence artificielle sur le diagnostic du cancer du poumon
WO2016163844A1 (fr) Puce de séparation de cellules et procédé de séparation de cellules l'utilisant
KR102157380B1 (ko) 분석용 일체형 칩장치
CN213957408U (zh) 一种血液蛋白的分析装置
WO2019054844A1 (fr) Bande de diagnostic utilisant un flux latéral
WO2020101347A1 (fr) Dispositif de détection de biomolécules mettant en oeuvre des micropores
JP6828088B2 (ja) 生化学検査と血液検査を同時に行うマルチシステム、及びこれに用いられるマルチディスク

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18757594

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18757594

Country of ref document: EP

Kind code of ref document: A1